Back to Search Start Over

Anti-HER2 Antibody, Trastuzumab in Patients with Recurrent or Refractory Ovarian or Primary Peritoneal Carcinoma with Overexpression of HER2

Source :
Clinical Oncology Alert. March 1, 2003
Publication Year :
2003

Abstract

Anti-HER2 Antibody, Trastuzumab in Patients with Recurrent or Refractory Ovarian or Primary Peritoneal Carcinoma with Overexpression of HER2 Abstract & Commentary Synopsis: The clinical value of single-agent trastuzumab in recurrent [...]

Details

Language :
English
ISSN :
08867186
Database :
Gale General OneFile
Journal :
Clinical Oncology Alert
Publication Type :
News
Accession number :
edsgcl.206595047